IBB News Alert Nasdaq Biotechnology Ishares (IBB) 275.23 09/19/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Nasdaq Biotechnology Ishares (IBB) 275.23 $IBB

'Fast Money' Recap: How Alibaba Is Hitting Momentum Stocks
at The Street - Tue Sep 16, 4:00AM CDT
The trading panel discussed Chinese stocks, Apple's new phone and whether Darden shares are worth buying.

iShares Nasdaq Biotechnology Index Falls 1.26% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Mon Sep 15, 3:57PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $263.64 to a high of $268.99. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $268.24 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

3 Reasons Actavis plc Stock Could Fall
George Budwell, The Motley Fool - Motley Fool - Mon Sep 15, 10:50AM CDT
Healthcare and biotechnology stocks have put on another amazing show this year, with the closely watched  iShares Nasdaq Biotechnology Index   pushing higher by nearly 19% so far. And certain subsectors, including generic and specialty...

WIT, IBB, EROC, MPX, SEP, TUZ Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Mon Sep 15, 4:16AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Wipro Ltd (NYSE:WIT), Ishares Nasdaq Biotechnology (NASDAQ:IBB), EAGLE ROCK ENERGY PARTNERS (NASDAQ:EROC), Marine Products Corp (NYSE:MPX), Spectra Energy Partners LP (NYSE:SEP), PimCo 1 3 Year Us Treasury Index Fund (NYSE:TUZ) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:

After Yesterday's Rally of 1.85% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Sep 10, 4:08PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $269.51 to a high of $274.64. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $273.23 on volume of 750,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

iShares Nasdaq Biotechnology Index Set to Possibly Pullback After Yesterday's Rally of 1.85%
Comtex SmarTrend(R) - Wed Sep 10, 4:07PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $269.51 to a high of $274.64. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $273.23 on volume of 750,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Biotech ETFs Slip on Gilead Weakness; Buying Opportunity Now? - ETF News And Commentary
Zacks Equity Research - ZACKS - Wed Sep 10, 11:00AM CDT
A look at biotech ETFs following some weakness in one of the key companies in the space, Gilead (GILD).

Watch for iShares Nasdaq Biotechnology Index to Potentially Rebound After Falling 1.65% Yesterday
Comtex SmarTrend(R) - Thu Sep 04, 3:50PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $270.23 to a high of $276.22. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $273.85 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

iShares Nasdaq Biotechnology Index Set to Possibly Rebound After Yesterday's Selloff of 1.65%
Comtex SmarTrend(R) - Thu Sep 04, 3:50PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $270.23 to a high of $276.22. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $273.85 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Are Biotech ETFs Back on Track? - ETF News And Commentary
Zacks Equity Research - ZACKS - Wed Aug 27, 7:00AM CDT
Recent trends have been very favorable for the biotech sector, but can this run continue?

After Recent Surge, Are Biotech ETFs Back on Track? - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Wed Aug 27, 7:00AM CDT
Recent trends have been very favorable for the biotech sector, but can this run continue?

Biotech Stock Boom Times Are Back
at The Street - Tue Aug 26, 6:00AM CDT
The iShares Nasdaq Biotechnology ETF closed at 272.63 Monday, less than one point below the year (and all-time) closing high reached on Feb. 25.

'Fast Money' Recap: Next Stop, S&P 2,100?
at The Street - Tue Aug 26, 4:00AM CDT
The trading panel looked at banks and the top buy and sell candidates for right now.

Look for Shares of iShares Nasdaq Biotechnology Index to Potentially Pullback after Yesterday's 2.33% Rise
Comtex SmarTrend(R) - Mon Aug 25, 4:07PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $268.75 to a high of $272.88. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $268.60 on volume of 1.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

After Yesterday's Rally of 2.33% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Aug 25, 4:06PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $268.75 to a high of $272.88. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $268.60 on volume of 1.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Economic Recovery Doesn't Satisfy Fed as Stocks Soar Higher
at The Street - Thu Aug 21, 10:14AM CDT
Low inflation and slack in the labor market has kept policymakers dovish, leading to strength in U.S. equities and in high-beta sectors.

Nasdaq Composite: What Are You Buying That's Driving New Highs? - Real Time Insight
Zacks Equity Research - ZACKS - Mon Aug 18, 1:04PM CDT
It's not just the big caps attracting all the money




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Savvas Launches Miller & Levine Biology Program Revamp

Updated Category News Views 35

Education Meets Innovation: Savvas Takes a Bold Step Who would have thought biology education could get a makeover that might actually stick? Savvas Learning Company thinks it's onto something with the launch of the all-new Miller & Levine Experience Biology Program. The spotlight's on innovation—it's about time someone shook up the way high schoolers learn biology. A...

Continue Reading
Factory-Built Homes Take Center Stage in New Doc Short

Updated Category News Views 88

Housing is one of those things we all think we understand until we start peeling back the layers of its history, especially when factory-built homes are involved. Here's a new angle: Clayton has just released the teaser for their documentary short, "Built: A Story of Factory-Built Housing in America," and it's turning the lights on a sector that's often left in the...

Continue Reading
transcosmos: Not Just Calls—Evolving Business Strategy

Updated Category News Views 110

Turning Talk into Triumphs Award chatter isn't exactly rare in this industry, but the latest accolades rolling in for transcosmos from the Best Contact Center Indonesia 2026 ain't your run-of-the-mill pat on the back. Sure, a trophy's a trophy, but when they snatch Gold in the Business Contribution category and another shiny Silver in People Development, it’s hinting at...

Continue Reading
Unicycive Faces Legal Heat: Shareholder Lawsuit Looms

Updated Category News Views 104

The Unicycive Landslide: What Went Down? Investors, buckle up. Unicycive Therapeutics Inc. (NASDAQ: UNCY) finds itself deep in the muck of a securities class action. Chief honchos, CEO Shalabh Gupta and CFO John Townsend, are taking the heat for allegedly controlling company disclosures that led shareholders to believe in non-existent progress with their third-party...

Continue Reading
SoftwareOne Triumphs in 2026 GitHub Partner Awards

Updated Category News Views 43

SoftwareOne Nabs Prestigious GitHub Honor Outta nowhere, SoftwareOne's been lashed onto the center stage, bagging GitHub's Global Channel Sales Partner of the Year for 2026. This ain't just another shiny trophy on the shelf; it's a solid nod to their grit and strategy. Now, if good old GitHub says you're their top dog, you're obviously doing something right. Not bad for a...

Continue Reading
Data Centers Drive Surge in Power and Cooling Demand

Updated Category News Views 23

Data Centers: The Unseen Powerhouses Don't let the tech jargon fool you—data centers are more than just server rooms. They're beastly energy guzzlers, and their demand is rippling through the supply chain in a big way. You've got companies like Vertiv, American Tower, Johnson Controls, and Generac riding high on this trend, making some serious waves in their quarterly...

Continue Reading
Data Breach at Lumara Bio: Privacy Lawsuits Loom

Updated Category News Views 28

Another Day, Another Data Breach It seems like you can’t throw a stone without hitting a data breach these days—and this time, it’s Lumara Bio USA’s turn under the spotlight. The Princeton-based oncology therapeutics outfit, part of Germany’s ITM Isotope Technologies, spilled some beans it never meant to. We're talking some pretty sensitive stuff here, folks....

Continue Reading
Jacobi's Harness Brings AI from Concept to Reality

Updated Category News Views 160

The Challenge of Moving AI to Production Diving headfirst into AI in finance? Well, Jacobi's bold move with their new toy, the Investment Management Harness, spotlights a filthy secret: the hurdles between a big idea and execution are seldom technological. We got AI shaving prototyping time down to just days, yet pushing to production? That's a marathon in itself. Boards...

Continue Reading
Air Canada-CAE Scholarship Drives Women in Aviation

Updated Category News Views 88

A New Chapter for Women in Aviation Call it paving the skies or busting the glass cockpit ceiling, but Air Canada and CAE are really doubling down on getting more women into aviation. They're rolling out the eighth annual Captain Judy Cameron Scholarship, set to open applications on November 1, 2026. With up to eight scholarships on the table for Canadian women eyeing...

Continue Reading
H.R. 10549: Hope Charities Pushes for Pharmacy Freedom

Updated Category News Views 63

Hope Charities Takes a Stand for Patients In Prairieville, Hope Charities is throwing its weight behind a bill they believe is brewing up a patient revolution. The Patients Choice in Specialty Pharmacy Act, otherwise known as H.R. 10549, sparked by Representatives Neal Dunn and Joe Wilson, tackles the comfortable partnerships some insurers have been enjoying with their...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative AI Assistant by ClickBid Revolutionizes Fundraising

Updated Category News Views 155

ClickBid Introduces Groundbreaking AI Assistant ClickBid, recognized as a pioneer in event fundraising technology, proudly presents ClickBid Search. This is the first custom GPT-powered AI assistant tailored specifically for nonprofits, designed to offer immediate and relevant answers to help organizations optimize their event strategies. Available at no cost to all...

Continue Reading
TIER IV and TUM Drive Level 4 Autonomous Cars

Updated Category News Views 25

Autonomous Driving Gets a German Boost Well folks, looks like the autonomous vehicle scene is hitting the autobahns with more horsepower than ever before. Today’s chatter is all about how TIER IV and the Technical University of Munich (TUM) have teamed up, tapping into the grid as they ride the waves of cutting-edge NVIDIA tech. The Sparks Under the Hood: NVIDIA...

Continue Reading
Vericel Corporation's Upcoming Presentation at MedTech Conference

Updated Category News Views 147

Vericel Corporation's Engagement at the MedTech Conference CAMBRIDGE, Mass. — Vericel Corporation (NASDAQ:VCEL), a recognized leader in advanced therapies for sports medicine and severe burn care, has exciting news regarding its participation at the upcoming Truist Securities MedTech Conference. The company will be featured in a fireside chat, slated to take place at...

Continue Reading
Gildan Achieves Strong Q2 Results: Revenue and Finances Surge

Updated Category News Views 128

Gildan Reports Remarkable Growth in Second Quarter Earnings Gildan Activewear Inc. (NYSE: GIL, TSX: GIL) has achieved record net sales of $919 million during the second quarter, reflecting a strong 6.5% increase compared to the previous year. Strong Operational Performance and Profitability This quarter's operating margin stood at an impressive 21.7%, with an adjusted...

Continue Reading
MimiVax and UI Pharmaceuticals Mark Key Production Milestone

Updated Category News Views 260

MimiVax and UI Pharmaceuticals Mark Key Production Milestone MimiVax and UI Pharmaceuticals have achieved an exciting development in the field of cancer treatment with the clinical manufacture of SurVaxM, an innovative immunotherapeutic vaccine aimed at targeting glioblastoma. SurVaxM proudly stands out as the first product to be manufactured at UI Pharmaceuticals' newly...

Continue Reading